NASDAQ
SLP

Simulations Plus Inc

Health Information Services
Healthcare

Prices are adjusted according to historical splits.

Simulations Plus Inc Stock Price

Vitals

Today's Low:
$40.84
Today's High:
$41.88
Open Price:
$41.84
52W Low:
$32.4413
52W High:
$57.3482
Prev. Close:
$41.87
Volume:
85731

Company Statistics

Market Cap.:
$834.34 million
Book Value:
8.501
Revenue TTM:
$55.68 million
Operating Margin TTM:
17.43%
Gross Profit TTM:
$43.08 million
Profit Margin:
18.66%
Return on Assets TTM:
3.32%
Return on Equity TTM:
5.99%

Company Profile

Simulations Plus Inc had its IPO on 1997-06-18 under the ticker symbol SLP.

The company operates in the Healthcare sector and Health Information Services industry. Simulations Plus Inc has a staff strength of 157 employees.

Stock update

Shares of Simulations Plus Inc opened at $41.84 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $40.84 - $41.88, and closed at $40.95.

This is a -2.2% slip from the previous day's closing price.

A total volume of 85,731 shares were traded at the close of the day’s session.

In the last one week, shares of Simulations Plus Inc have slipped by -8.8%.

Simulations Plus Inc's Key Ratios

Simulations Plus Inc has a market cap of $834.34 million, indicating a price to book ratio of 4.5652 and a price to sales ratio of 14.6587.

In the last 12-months Simulations Plus Inc’s revenue was $55.68 million with a gross profit of $43.08 million and an EBITDA of $11.86 million. The EBITDA ratio measures Simulations Plus Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Simulations Plus Inc’s operating margin was 17.43% while its return on assets stood at 3.32% with a return of equity of 5.99%.

In Q1.6666666666667, Simulations Plus Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 8.5%.

Simulations Plus Inc’s PE and PEG Ratio

Forward PE
62.5
Trailing PE
83.74
PEG
9.7712

Its diluted EPS in the last 12-months stands at $0.5 per share while it has a forward price to earnings multiple of 62.5 and a PEG multiple of 9.7712. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Simulations Plus Inc’s profitability.

Simulations Plus Inc stock is trading at a EV to sales ratio of 12.7426 and a EV to EBITDA ratio of 36.7544. Its price to sales ratio in the trailing 12-months stood at 14.6587.

Simulations Plus Inc stock pays annual dividends of $0.24 per share, indicating a yield of 0.57% and a payout ratio of 48%.

Balance sheet and cash flow metrics

Total Assets
$179.13 million
Total Liabilities
$9.02 million
Operating Cash Flow
$7.92 million
Capital Expenditure
$1.26 million
Dividend Payout Ratio
48%

Simulations Plus Inc ended 2024 with $179.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $179.13 million while shareholder equity stood at $169.39 million.

Simulations Plus Inc ended 2024 with $110000.00 in deferred long-term liabilities, $9.02 million in other current liabilities, 143666000.00 in common stock, $25.86 million in retained earnings and $12.92 million in goodwill. Its cash balance stood at $55.13 million and cash and short-term investments were $122.37 million. The company’s total short-term debt was $330,000 while long-term debt stood at $0.

Simulations Plus Inc’s total current assets stands at $137.31 million while long-term investments were $0 and short-term investments were $67.23 million. Its net receivables were $10.21 million compared to accounts payable of $357000.00 and inventory worth $0.

In 2024, Simulations Plus Inc's operating cash flow was $7.92 million while its capital expenditure stood at $1.26 million.

Comparatively, Simulations Plus Inc paid $0.48 in dividends in 2024.

Other key metrics

Current Trading Price
$40.95
52-Week High
$57.3482
52-Week Low
$32.4413
Analyst Target Price
$59.33

Simulations Plus Inc stock is currently trading at $40.95 per share. It touched a 52-week high of $57.3482 and a 52-week low of $57.3482. Analysts tracking the stock have a 12-month average target price of $59.33.

Its 50-day moving average was $46.48 and 200-day moving average was $42.58 The short ratio stood at 16.21 indicating a short percent outstanding of 0%.

Around 2016.6% of the company’s stock are held by insiders while 7725.1% are held by institutions.

Frequently Asked Questions About Simulations Plus Inc

The stock symbol (also called stock or share ticker) of Simulations Plus Inc is SLP

The IPO of Simulations Plus Inc took place on 1997-06-18

Similar Industry Stocks (Health Information Services)

Last Price
Chg
Chg%
$37.02
-0.13
-0.35%
$972.85
-64.7
-6.24%
$98.8
-8.3
-7.75%
$445.3
-3.96
-0.88%
$1.32
-0.03
-2.22%
$1039.8
11.5
+1.12%
$14.11
-0.32
-2.22%
$51.04
-4.15
-7.52%
$2.37
-0.01
-0.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.

Address

42505 Tenth Street West, Lancaster, CA, United States, 93534-7059